WEILL CORNELL MEDICINE — Tiny packets called extracellular vesicles and particles (EVPs), released by cancer and immune cells, contain specific proteins that may serve as reliable biomarkers for diagnosing early-stage cancer, according to investigators at Weill Cornell Medicine and Memorial Sloan Kettering.
A new study published August 13 in Cell identifies new biomarkers in EVPs that can be used to help discriminate these particles from others isolated from tissue and blood samples, so they can be used for analysis in diagnostic panels for detection of early malignancy. EVPs associated with cancer could also offer scientists valuable targets for drug development.
“One test tube of blood contains billions of EVPs,” said co-senior author Dr. David C. Lyden, Stavros S. Niarchos Professor in Pediatric Cardiology, and professor of pediatrics and of cell and developmental biology at Weill Cornell Medicine [and PSSCRA Scientific Review Council Member]. “This means a person with cancer has an abundant source of cancer-associated EVPs that clinicians could assess for diagnosis.”